Overview
Argireline is classified as a cosmetic peptide peptide. Topical wrinkle reduction, SNAP-25 inhibition, muscle relaxation (neurocosmetic).
Competes with SNAP-25 (synaptosomal-associated protein 25) for binding at the SNARE complex, partially inhibiting acetylcholine release at the neuromuscular junction, reducing repeated facial muscle contractions that cause dynamic wrinkles. Applied topically, it does not cross to the dermis at meaningful concentrations.
Also known as: Acetyl Hexapeptide-3, Acetyl Hexapeptide-8, AH-3
Category
Cosmetic Peptide
Route
Topical
FDA Status
Not Approved
How Does Argireline Work?
Competes with SNAP-25 (synaptosomal-associated protein 25) for binding at the SNARE complex, partially inhibiting acetylcholine release at the neuromuscular junction, reducing repeated facial muscle contractions that cause dynamic wrinkles. Applied topically, it does not cross to the dermis at meaningful concentrations.
At the molecular level, Argireline operates through pathways characteristic of the Cosmetic Peptide class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
Safety Profile
Considered very safe for topical use. No systemic absorption. Not approved for injection. Not an FDA-classified drug — classified as a cosmetic ingredient.
| Side Effect | Incidence | Severity |
|---|---|---|
| Mild skin irritation | Rare (<2%) | mild |
Sourcing Argireline for Research
If you're looking to source Argireline for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
* Research vendor — verify your regional regulations before purchase.
Full Research Profile
Argireline — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.